Skip to content
Peptigraph home
Shop Peptides50% off*

How to Inject Mazdutide: Sites, Syringes and Steps

Where to inject Mazdutide, which syringe to use, how to read units and the hygiene steps that prevent infection.

Medical review pendingGLP-1 / glucagon dual agonistUpdated
This is a general guide to subcutaneous injection, not a substitute for being shown by a nurse, pharmacist or doctor.

Injection sites

Most peptides are injected under the skin (subcutaneously), into the fatty layer rather than the muscle.

  • Belly: at least 2 inches (5 cm) away from the navel.
  • Front and outer thighs.
  • Back of the upper arms, if someone else can reach it.
  • Rotate sites each time and avoid skin that is bruised, scarred or irritated.

Syringe and needle

U-100 insulin syringes are marked in units: 100 units equal 1 mL, so 10 units is 0.1 mL. They come in 0.3, 0.5 and 1 mL sizes; a smaller syringe has finer marks and is easier to read for small doses. Needle length and gauge used for Mazdutide in studies: not reported in study abstracts (PubMed search, 2 Oct 2026).

How to read an insulin syringe

Step by step

  1. 1Wash your handsUse soap and water, and work on a clean surface.
  2. 2Check the vialLabel, lot and date present; solution clear with no particles. Mixing a powder vial first? Use sterile bacteriostatic water.
  3. 3Clean the vial top and the siteWipe both with an alcohol swab and let them dry.
  4. 4Draw the dosePull the plunger to the units mark for your dose, then tap out air bubbles and re-check the mark.
  5. 5InjectPinch a fold of skin, insert the needle at 45 to 90 degrees, push the plunger slowly and wait a few seconds before withdrawing.
  6. 6Dispose safelyPut the used syringe straight into a sharps container. Never reuse or share needles.
How to reconstitute a peptide vial

Route and schedule in the trials

In the US phase 2 trial, adults received once-weekly subcutaneous injections of placebo or mazdutide for 48 weeks.[6]

The phase 3 GLORY-1 trial gave 4 mg or 6 mg of mazdutide, or placebo, for 48 weeks.[7]

The phase 1b study gave once-weekly subcutaneous injections for 12 weeks with 8 weeks of safety follow-up.[8]

How trial doses were stepped up

Its dose-escalation regimens stepped from 1.0 to 3.0 mg, 1.5 to 4.5 mg and 2.0 to 6.0 mg in 4-week steps.[8]

In the US trial, the 3-6 mg group stayed on 3 mg from week 4 to week 32 before escalating to 6 mg at 32 weeks.[6]

What is not available

No label exists for mazdutide in the US, UK, Canada or Australia lookups, so there are no regulator-written injection steps, site rotation or pen instructions to quote.

Calculated from labels found 0; lookups Drugs@FDA, emc, Health Canada DPD, TGA ARTG. Formula: labels found across 4 lookups = 0

Common questions

Where do you inject Mazdutide?

Under-the-skin (subcutaneous) injections are usually given in the belly, at least 2 inches from the navel, the front of the thighs or the back of the upper arms. Rotate sites each time.

What syringe is used for Mazdutide?

Vials are usually drawn with a U-100 insulin syringe, where 100 units equal 1 mL. Common sizes hold 0.3, 0.5 or 1 mL. Match the syringe to the dose so the mark is easy to read.

How often is Mazdutide injected?

The interval comes from the study or prescription, not from this guide. See the dosage page for what studies used.

How is mazdutide injected?

In the trials it was a once-weekly subcutaneous injection; no pen or device instructions are cited.[8]

More on Mazdutide

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.Legal statusFDA, compounding and WADA status with dates.For diabetesWhat research says about Mazdutide for diabetes.BenefitsClaimed benefits next to what published studies measured.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  2. 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3PubMed search: mazdutide[tiab] OR IBI362[tiab] OR LY3305677[tiab] (53 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  4. 4PubMed search: (mazdutide[tiab] OR IBI362[tiab] OR LY3305677[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (31 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search: (mazdutide[tiab] OR IBI362[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (1 result)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.The lancet. Diabetes & endocrinology · 2026PMID 42628555Accessed 2 Oct 2026
  7. 7Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.The New England journal of medicine · 2025PMID 40421736Accessed 2 Oct 2026
  8. 8IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.EClinicalMedicine · 2021PMID 34430840Accessed 2 Oct 2026

Found an error? Report a correction.